Gamida Cell

$2.76 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Gamida Cell

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).

Stock Analysis

last close $2.76
1-mo return -29.2%
3-mo return -41.3%
avg daily vol. 475.24T
52-week high 15
52-week low 2.68
market cap. $172M
forward pe -
annual div. -
roe -171.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 40.5%
baraka

Subscribe now for daily local and international financial news

Subscribe